PLX
What one share of Protalix BioTherapeutics holds
Biological Products, (No Diagnostic Substances)
We are a commercial stage biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs. We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression in suspension.
Protalix BioTherapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.99 |
|---|---|
| Profit | $0.23 |
| Capex (buildings and equipment) | $0.03 |
| Free cash flow | $0.09 |
| Cash and investments | $0.34 |
| Book value | $0.89 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.91 | −$2.90 | $0.08 | −$3.25 | — | −$0.80 |
| 2017 | $1.61 | −$6.37 | $0.07 | −$0.84 | — | −$2.05 |
| 2018 | $2.33 | −$1.80 | $0.05 | −$0.57 | — | −$3.56 |
| 2019 | $3.69 | −$1.23 | $0.04 | −$1.35 | — | −$4.74 |
| 2020 | $2.16 | −$0.22 | $0.02 | −$0.92 | — | −$0.78 |
| 2021 | $0.87 | −$0.62 | $0.03 | −$0.27 | — | −$0.13 |
| 2022 | $0.98 | −$0.31 | $0.01 | −$0.53 | — | −$0.20 |
| 2023 | $0.79 | $0.09 | $0.01 | −$0.03 | — | $0.46 |
| 2024 | $0.66 | $0.04 | $0.02 | $0.09 | — | $0.57 |
| 2025 | $0.67 | −$0.08 | $0.02 | −$0.17 | — | $0.60 |